Clinical Trials
1,176 trialsSACHI
Hutchmed
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
MK-3475-01C
Merck Sharp & Dohme LLC
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Sunshine Lake Pharma Co., Ltd.
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
ZEAL-1L
GlaxoSmithKline
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
NAVIGATE
Bayer
AURA
AstraZeneca
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
ENSPIRIT
Achieve Life Sciences
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
AstraZeneca
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
TraveraRTGx
Travera Inc
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sandoz
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Novartis
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Amgen
ATLANTIC
AstraZeneca
GeoMETry-C
Novartis
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
PEARLS
Merck Sharp & Dohme LLC
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
MK-4700-001
Merck Sharp & Dohme LLC
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Ono Pharmaceutical Co., Ltd.
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
UNCOVER
AstraZeneca
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
Akeso
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
LEAP-007
Merck Sharp & Dohme LLC
MK-1084-009
Merck Sharp & Dohme LLC
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
BeOne Medicines
MK-7684A-007
Merck Sharp & Dohme LLC
SKYSCRAPER-06
Hoffmann-La Roche
SKYSCRAPER-15
Hoffmann-La Roche
SKYSCRAPER-01
Hoffmann-La Roche
Balise
Eli Lilly and Company